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Abstract Insulin receptors in the brain are found in high
densities in the hippocampus, a region that is fundamentally
involved in the acquisition, consolidation, and recollection
of new information. Using the intranasal method, which
effectively bypasses the blood–brain barrier to deliver and
target insulin directly from the nose to the brain, a series of
experiments involving healthy humans has shown that in-
creased central nervous system (CNS) insulin action enhan-
ces learning and memory processes associated with the
hippocampus. Since Alzheimer's disease (AD) is linked to
CNS insulin resistance, decreased expression of insulin and
insulin receptor genes and attenuated permeation of blood-
borne insulin across the blood–brain barrier, impaired brain
insulin signaling could partially account for the cognitive
deficits associated with this disease. Considering that insulin
mitigates hippocampal synapse vulnerability to amyloid
beta and inhibits the phosphorylation of tau, pharmacological
strategies bolstering brain insulin signaling, such as intranasal
insulin, could have significant therapeutic potential to deter
AD pathogenesis.
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Insulin's Scientific Journey from the Periphery
to the Brain: a Short Historical Overview
In 1916, the Romanian scientist Nicolae Paulescu showed
for the first time that insulin, when injected into diabetic
dogs, had a normalizing effect on blood sugar levels [1].
Further research revealed that the ability of certain tissues,
such as the skeletal muscle, to utilize glucose essentially
depends on the insulin signal [2], while that of the brain was
considered insulin-independent [3]. As a consequence, the
general scientific interest in the role insulin might play for
brain functions abated. This interest was only revived when
insulin receptors (IRs) were ubiquitously detected in both
rodent and human brains [4–6]. The fact that IRs are widely
expressed in the brain, combined with evidence that insulin
crosses the blood–brain barrier (BBB) by a saturable,
receptor-mediated transport mechanism [7], challenged
prevailing scientific concepts that the brain would not be
sensitive to insulin, and thus reawakened the scientific interest
related to the influence of this hormone on brain functions.
IRs are found in particularly high densities in the
hippocampus [4]. This central site is fundamentally involved
in the acquisition, consolidation, and recollection of informa-
tion [8]. In the next section, we will summarize current
evidence suggesting that brain insulin signaling influences
learning and memory under physiological-like conditions. It
is important to keep in mind that insulin also affects neural
circuits involved in the regulation of food intake and energy
expenditure (e.g., [9–11]). In order to gain a comprehensive
overview regarding the impact of brain insulin pathways on
whole-body energy homeostasis, the interested reader is
referred to [12–14].
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Effects of Insulin on Memory Processing:
from the Needle to the Nose
Hippocampal damage causes severe impairments in the
ability of rodents to learn and remember a location in space
[15], highlighting that the hippocampus is an essential
support for place memory. Using the intracerebroventricular
route, several studies have consistently proven that insulin
benefits spatial memory formation by acting at hippocampal
sites [16, 17]. For instance, rats receiving an intracerebro-
ventricular injection of insulin after they had been shocked
when entering a darkened compartment show an increased
latency to enter the same place in a recall session 24 h later
[17]. This suggests that insulin enhances memory for the
negative consequences associated with spatial orientation.
In humans, it has been shown that postprandial-like
increases in plasma insulin levels are followed by increases
in cerebrospinal fluid levels of this hormone, indicating that
plasma insulin accesses the brain, and therefore potentially
affects memory function in humans [18]. Consistent with
this assumption, euglycemic hyperinsulinemic clamps have
shown that higher, compared to lower doses of intravenous
insulin improved verbal memory performance in healthy
young men [19]. There are, however, some caveats with this
method which limit conclusive interpretation of the data. The
continuous glucose infusion during the hyperinsulinemic
clamp procedure to ensure euglycemia may exert a biasing
impact on cognitive functioning. Moreover, systemic insulin
infusions acutely increase serum cortisol levels in healthy
men [20], a hormone which is known to influence core
mechanisms of memory processing [21].
One way to minimize these methodological biases and
reduce or avoid systemic exposure to insulin while targeting
the brain is intranasal administration. The efficacy of the
intranasal administration route to deliver substances directly
to the brain has been proven in various experimental
settings. For instance, in 1970, in a landmark study, de
Lorenzo demonstrated in squirrel monkeys that intranasally
administered gold particles translocated from the nasal cavity
to the olfactory bulb. In 1986, experiments in mouse, rat,
and squirrel monkey expanded these results by showing
that intranasally administered horseradish peroxidase
passed freely through intercellular junctions of the olfactory
epithelia to reach the olfactory bulbs of the CNS extra-
cellularly within 45–90 min [22]. In 1989, Frey first
proposed the noninvasive intranasal method for bypassing
the BBB to target therapeutic proteins, growth factors, and
hormones (including insulin) to the brain to treat neuro-
degenerative disorders such as Alzheimer's disease [23, 24]
and later expanded on the specific use of intranasal insulin to
target the brain to treat Alzheimer's disease and other CNS
disorders [25, 26]. In 2004, Thorne et al. demonstrated in
rodents that intranasal insulin-like growth factor I not only
bypassed the BBB to reach the brain within 30 min but
did so by traveling extracellularly along both the olfactory and
trigeminal neural pathways [27]. The mechanisms involved in
the direct intranasal delivery and targeting of therapeutics to
the CNS that allow drugs to bypass the BBB have been
reviewed elsewhere [28]. Using this method, Born et al. were
the first to demonstrate that intranasally administered
neuropeptides, including insulin and melanocortin [4–10],
bypass the bloodstream to reach the cerebrospinal fluid within
10 min ([29]; Fig. 1). Experiments in humans have shown that
intranasal insulin exerts rapid effects on EEG parameters
[30, 31], indicating that following intranasal administration,
a significant amount of insulin reaches the brain in a
functionally active state. In the next section, we will
highlight evidence demonstrating that intranasal insulin
improves memory function in healthy young humans.
Intranasal Insulin: a Memory Enhancer in Humans?
To examine whether enhanced brain insulin signaling affects
hippocampus-dependent memory processing in humans, in
a previous intranasal experiment, 38 students of normal
body weight (body mass index (BMI) <25 kg/m²; 14 females)
were assigned into two groups receiving intranasally either
placebo or regular human insulin (160 IU/day) during an
8-week treatment phase [32]. At the beginning and end
of treatment, i.e., after the first intranasal administration
and after 7 weeks of intranasal treatment, lists of 30
words were verbally presented to the subjects and immediate
recall was measured after a distraction interval of 3 min. In a
delayed recall, which took place 1 week later, subjects wrote
down all words they could remember from the list presented
before. In comparison to placebo, delayed recall of words
significantly improved after 8 weeks of intranasal insulin
administration whereas immediate recall was generally not
affected (Fig. 2a). This was the first demonstration that
intranasal insulin improves memory in humans. Blood
glucose and plasma insulin levels did not differ between
the placebo and insulin groups. Employing the same
study design as presented above [32], these results have
been confirmed in additional experiments involving either
obese men treated with regular human insulin [33], or normal
weight men treated with the insulin analogue insulin aspart
[34]. While the delayed onset of insulin's action on memory
points to the involvement of more gradual plastic pro-
cesses determining neuronal function, recent data also
indicate that a single dose of intranasal insulin acutely
improves hippocampus-dependent memory in both young
[9] and middle-aged [35] women. These experimental
data clearly support a role of brain insulin signaling
pathways in the formation of hippocampus-dependent
memory in healthy humans.
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Insulin Resistance, Cognitive Function, and Alzheimer's
Disease: Is There a Link?
Insulin resistance, a key metabolic disturbance of type 2
diabetes, is characterized by reduced responsiveness of target
tissues to the insulin signal. Results from population-based
studies suggest that insulin resistance is tightly linked to
cognitive impairment and smaller brain size [36, 37]. These
epidemiological data have been supplemented by recent
results showing that men with enhanced peripheral insulin
resistance have reduced spontaneous cortical activity, as
assessed by magnetoencephalography during euglycaemic
insulin infusion [38]. In this study, intravenous infusions of
insulin in insulin-resistant subjects induced no changes in beta
band activity (commonly associated with increased cortical
processing activity; [39]) and even a decrease of theta band
activity (well known to be related to increased memory
performance; [40]) as assessed by magnetoencephalography.
In contrast, insulin-sensitive controls showed increased
activity in both beta and theta bands in response to intrave-
nous insulin [38]. Further, as revealed by fludeoxyglucose
F 18 positron emission tomography (PET), greater insulin
resistance has also been linked to reduced cerebral glucose
metabolic rates in frontal, parietotemporal, and cingulate
regions in elderly, a pattern associated with Alzheimer's
disease [41]. These findings therefore provide important
evidence supporting the hypothesis that brain insulin
signaling is of biological significance for memory functions
in humans. This might not be surprising as there is some
evidence, albeit limited, that insulin facilitates regional
glucose uptake and utilization in the brain [42].
Remarkably, disturbances in brain insulin signaling have
been previously linked to Alzheimer's diseases (AD) [43].
While one study of Japanese patients with AD reported
increased fasting levels of cerebrospinal fluid (CSF) insulin
[44], other studies have shown that patients suffering from
AD show reduced brain IR activity along with lower CSF
insulin levels and peripheral hyperinsulinemia [45, 46] and
attenuated insulin and insulin-like growth factor receptor
expression [47]. This suggests that disrupted brain insulin
signaling may contribute to the loss of memory functions
associated with this disease. Since insulin can mitigate the
synaptic loss of hippocampal neurons induced by amyloid
beta [48] and regulate glycogen synthase kinase-3 beta,
thereby inhibiting the phosphorylation of tau protein that
forms neurofibrillary tangles which are a further pathological
feature of AD [49], impaired CNS signaling of the hormone
may also promote brain atrophy associated with AD [50].
Against this background, strategies that increase brain insulin
concentrations may be expected to counteract AD-related





in cerebrospinal fluid (CSF)
before and within 80 min
after intranasal administration
of human insulin (40 IU;
solid lines, n08) and placebo
(dashed lines, n05) Substances
were administered with a nasal
spray atomizer. Nose symbol
indicates time of substance
administration. Means ± SEM
are indicated. **P value smaller
than 0.01, *P value smaller than
0.05, for pairwise comparisons
of baseline adjusted values
between both conditions
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memory deficits and may have therapeutic potential to deter
AD pathogenesis. Supporting this assumption, enhancing
brain insulin levels in AD patients by intravenous insulin
administration has been shown to acutely improve per-
formance on a hippocampus-dependent memory task
[51]. However, owing to the notion that high systemic
doses would be needed to achieve functionally effective
insulin concentrations in the brain, this mode of administra-
tion is not viable in the clinical setting. In contrast, intranasal
insulin is a promising approach enabling the selective
elevation of CNS insulin levels while circumventing risks
associated with peripheral administration. As detailed in
the next section, convincing evidence has been presented
that supports a beneficial effect of intranasal insulin on
hippocampus-dependent memory functions in patients
with early AD or its prodrome, amnestic mild cognitive
impairment (MCI).
Enhancing Brain Insulin Signaling Improves Memory
Functions in AD Patients
In a study published in 2006, Reger and coworkers
evaluated acute effects of a single intranasal administra-
tion of insulin (20 and 40 IU, respectively) on the ability
of cognitively impaired patients (i.e., AD and MCI) to
recall parts of a story [52]. In detail, subjects heard a
brief narrative containing 44 parts of information from a
story and were asked to recall as much as possible both
immediately and after a 10-min delay. Total verbatim
recall was scored. After intranasal administration of either
dose of insulin, story recall was particularly improved in those
patients who were Epsilon 4 (ε4) negative, with highest
performance after 20 IU. The ε4 allele belongs to the
apolipoprotein E gene and represents a strong genetic
risk factor for late-onset AD [53]. These beneficial
effects of intranasal insulin on verbal memory perfor-
mance were confirmed in separate experiments in that
insulin-treated patients retained more verbal information
compared with the placebo-assigned group (see also
Fig. 2b; [54, 55]). In a very recently published clinical
trial including 104 adults with amnestic MCI or mild to
moderate AD, 4 months of intranasal insulin administration
(20 IU insulin/day) preserved not only general cognition
but also improved the metabolic integrity of the brain, as
indicated by a fludeoxyglucose F 18 PET [56]. These
results suggest that targeting the brain insulin pathway by
means of intranasal administration of the hormone is a
promising therapeutic strategy to improve memory and
potentially deter the process of this devastating disease.
Of note, in two of these studies, benefits in episodic
memory were found only in those who received a daily
dose of 20 IU insulin, while those who received 40 IU
did not show an improved recall of episodic memory [54, 56].
These data suggest that intranasal insulin may dose-
dependently improve the recall of episodic memories in AD
patients. However, it might be also that a larger sample size or
a larger set of cognitive tests may also show beneficial effects
of 40 IU insulin on episodic memory. Thus, more research to
address these issues is needed.
Fig. 2 a Intranasal insulin improves memory in humans [data from [32]].
Immediate and delayed word list recall in healthy humans following 7
(immediate recall) and 8 weeks (delayed recall) of intranasal administration
of regular human insulin (160 IU/day, black bars, n019) and placebo
(white bars, n019), respectively. Immediate recall was tested 3 min after
the auditory presentation of 30 nouns (e.g., car, tree, and chocolate).
Delayed recall of the same list of nouns was tested after one more week
of treatment. Baseline adjusted means ± SEM are indicated. b Intranasal
insulin improves memory in patients withMCI or in the early stages of AD
[data from [55]]. Mean memory saving scores (±SEM) in patients with
early stage Alzheimer's disease and mild cognitive impairment
(MCI) at baseline (day 0) and after 21 days of treatment with
placebo (n012) and insulin (2×20 IU/day; n013), respectively.
Insulin-treated patients showed increased memory savings over the
21-day period relative to placebo. *P value smaller than 0.05
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At this point, it is important to emphasize that AD and
MCI patients carrying at least one copy of the ε4 allele did
not benefit from treatment [52, 54]. One possible explana-
tion for these discrepant results could be that dose–response
curves differ by apolipoprotein E genotype. This view is
supported by previous findings showing that AD patients
without ε4 showed both lower insulin-mediated glucose
disposal rates and significant memory facilitation in the
hyperinsulinemic condition than did AD patients carrying
at least one copy of the ε4 allele [57], suggesting that
defective insulin action may be of particular pathophysiologic
significance for patients without an epsilon 4 allele.
Thus, it is possible that even the lowest intranasal insulin
dose was still too high to induce memory benefits in ε4+
subjects. Alternatively, treatment response differences between
APOE groups may reflect differences in the amount of insulin
transported to the CNS following intranasal administration.
Future research is required to explore these possibilities.
Nevertheless, these findings have piloted an approach
that may improve memory function in patients with AD
and support further investigation of the benefits of intranasal
insulin for patients with Alzheimer's disease. An alternative
strategy, which may overcome central insulin resistance in
AD that warrants further exploration, involves improving
the brain's response to the insulin signal. As mentioned
earlier, patients suffering from AD show not only lower
CSF insulin levels [45] but also a reduced IR activity
[46], which could represent a promising target for thera-
peutic intervention. Insulin sensitizers like the peroxisome
proliferator activate receptor gamma agonist rosiglita-
zone, for example, which might exert its enhancing
effects on insulin sensitivity not only in the periphery but
also in the CNS. Accordingly, an improved memory function
in patients with AD was observed under treatment with rosi-
glitazone [58]. However, these findings have not been con-
firmed in a subsequent clinical trial [59], highlighting the need
to find alternative strategies to counteract the reduced brain IR
activity in AD patients.
Clinical Safety of Intranasal Insulin Administration
Peripheral insulin elevations have been previously linked to
synchronous increases in circulating and CSF concentra-
tions of amyloid beta [60], elevated blood pressure [61],
and enhanced hypothalamo–pituitary–adrenal [20] secretory
activity. In contrast, subchronic elevations of CNS insulin
concentrations by intranasal administration of the hormone
have been associated with reduced circulating concentra-
tions of amyloid beta [55], no changes in blood pressure
[62], and dampened hypothalamo–pituitary–adrenal (HPA)
secretory activity [32], indicating that shorter periods of
intranasal insulin apparently do not produce harmful side
effects in humans. However, as there is evidence linking
reduced insulin signaling in the rodent brain to longevity
[63], larger studies of longer duration are definitely needed
to allow final conclusions regarding the clinical safety of
insulin treatment in AD.
Concluding Remarks
Approximately six decades after insulin was discovered by
Nicolae Paulesco [1], insulin receptors were ubiquitously
found in the CNS [4] and thus challenged prevailing concepts
that the brain is an insulin insensitive organ. In aggregate, the
studies briefly summarized above clearly support the idea that
brain insulin signaling contributes to hippocampus-dependent
learning and memory processes in humans. Further, these
studies suggest that enhancing insulin signaling in the brain
by means of intranasal administration may be a useful thera-
peutic option to overcome the CNS insulin resistance found in
AD. Employing the combination of insulin sensitizers with
intranasal insulin might be another fruitful research direction
in order to treat CNS insulin resistance found in AD.
However, some caution is needed when interpreting the
effects of intranasal insulin on memory in AD patients.
Although promising, the observed effects were small in size
in absolute terms and the treatment period was relatively
short compared to the duration of AD, and therefore needs
confirmation in larger studies of longer duration, in order to
fully evaluate the therapeutic potential of intranasal insulin in
the treatment of AD. Further, it cannot be ruled out that CNS
insulin resistance, under yet unknown pathological condi-
tions, might represent a homeostatic mechanism to counteract
chronically elevated CSF concentrations of insulin.
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